Emactuzumab Dosing Cycles for TGCT Tumor Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a safe and effective treatment for tenosynovial giant cell tumors (TGCT) that can reduce disability and restore joint function, as current therapies like pexidartinib are associated with severe side effects and the standard of care, surgical resection, leads to significant morbidity.
Innovation Solution
A short-term treatment regimen involving up to five cycles of administering an antibody or antigen-binding fragment that specifically binds to the colony stimulating factor-1 receptor (CSF-1R), with each cycle consisting of a dose ranging from 200 mg to 1,500 mg followed by a rest period of 6 to 20 days, to manage TGCT.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical resection is used as standard of care, then tumor removal is achieved, but significant postsurgical morbidity occurs including removal of major tendons, neurovascular structures, or limbs
Solution Approach 1:
The patent replaces the mechanical surgical resection system with a biochemical therapy system using pexidartinib, a CSF-1R inhibitor. This substitution allows tumor treatment without physical removal, thereby avoiding damage to surrounding anatomical structures such as tendons, neurovascular structures, and limbs while maintaining tumor control efficacy
2Reliability
If pexidartinib is administered for TGCT treatment, then tumor shrinkage is achieved, but serious and potentially fatal liver injury occurs
Solution Approach 1:
The patent modifies the dosing parameters of pexidartinib by implementing intermittent cycling regimens (e.g., 21 days on treatment followed by 7 days off, or 14 days on followed by 7 days off) rather than continuous administration. This parameter change allows the liver to recover during treatment-free intervals while maintaining cumulative tumor shrinkage efficacy, thereby reducing the risk of fatal liver injury
3Duration of action of stationary object
If long-term continuous treatment is administered, then durable tumor response is achieved, but cumulative toxicity increases
Solution Approach 1:
The patent implements periodic treatment cycles where patients receive pexidartinib for a defined duration (e.g., 21 consecutive days) followed by treatment-free intervals (e.g., 7 days off). This periodic administration pattern sustains durable tumor response through repeated exposure while allowing toxin clearance and organ recovery during intervals, thereby managing cumulative toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This regimen demonstrates a pronounced and durable tumor shrinkage with improved joint function and pain reduction, along with a manageable safety profile, as shown in clinical studies.
Implementation Method 1
an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R)
Data Source
AI summary
The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods.